Tilray Brands (NASDAQ:TLRY) Stock Rating Upgraded by Roth Mkm

Tilray Brands (NASDAQ:TLRY) was upgraded by stock analysts at Roth Mkm from a “neutral” rating to a “buy” rating in a note issued to investors on Thursday, Marketbeat reports. The brokerage presently has a $10.00 price objective on the stock. Roth Mkm’s price objective would indicate a potential upside of 62.87% from the company’s previous close.

Several other equities analysts have also recently commented on TLRY. Zacks Research raised shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 11th. TD Cowen lowered their target price on shares of Tilray Brands from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Tilray Brands in a report on Wednesday, January 21st. Wall Street Zen upgraded shares of Tilray Brands from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Finally, ATB Cormark Capital Markets upgraded Tilray Brands from a “strong sell” rating to a “hold” rating in a research report on Wednesday, December 10th. Three investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $11.75.

Tilray Brands Stock Performance

Shares of TLRY opened at $6.14 on Thursday. Tilray Brands has a 52-week low of $3.51 and a 52-week high of $23.20. The stock’s 50-day simple moving average is $7.37 and its 200 day simple moving average is $10.25. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.72 and a current ratio of 2.81. The stock has a market capitalization of $715.35 million, a price-to-earnings ratio of -0.28 and a beta of 1.96.

Tilray Brands (NASDAQ:TLRY) last posted its earnings results on Thursday, January 8th. The company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.12. Tilray Brands had a negative return on equity of 6.35% and a negative net margin of 251.69%.The business had revenue of $217.51 million during the quarter, compared to analyst estimates of $211.15 million. During the same quarter in the previous year, the firm earned ($0.03) EPS. Research analysts forecast that Tilray Brands will post -0.2 EPS for the current fiscal year.

Hedge Funds Weigh In On Tilray Brands

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Tidal Investments LLC increased its holdings in shares of Tilray Brands by 15.0% in the 2nd quarter. Tidal Investments LLC now owns 28,971,835 shares of the company’s stock worth $12,006,000 after buying an additional 3,776,410 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of Tilray Brands by 281.0% during the 3rd quarter. Millennium Management LLC now owns 4,942,319 shares of the company’s stock worth $8,550,000 after acquiring an additional 3,645,060 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Tilray Brands in the third quarter worth $5,813,000. Ausdal Financial Partners Inc. bought a new position in Tilray Brands in the second quarter valued at $939,000. Finally, Scientech Research LLC bought a new position in Tilray Brands in the third quarter valued at $1,748,000. Hedge funds and other institutional investors own 9.35% of the company’s stock.

More Tilray Brands News

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Record revenue and top-line beat — Tilray reported roughly $206.7–$207M in Q3 revenue (about +11% organic) and beat consensus, with gross profit rising to ~$55M, showing improvement in core sales. Tilray Brands Delivers Record Q3 Fiscal 2026 Results
• Positive Sentiment: Strong international cannabis growth — management highlighted a 73% increase in international cannabis revenue and a 100% rise in flower volume year-over-year, supporting the company’s global cannabis thesis. Tilray Brands Delivers Record Q3 Fiscal 2026 Results (Yahoo)
• Positive Sentiment: Strategic beverage and brand moves — Tilray closed the BrewDog acquisition (~£40M) and is expanding branded RTD offerings (Popsicle partnership, new Shock Top SKU), which could boost longer-term beverage scale if margins improve. Is Tilray Among the 11 Best Marijuana Stocks? (InsiderMonkey)
• Neutral Sentiment: Company reaffirmed FY26 outlook — management kept guidance intact, which removes some downside but didn’t materially exceed street expectations. Tilray Brands reaffirms outlook after record quarter
• Neutral Sentiment: Earnings call highlighted strategy and execution challenges — management discussed growth initiatives and margin work in beverages and international markets; these are strategic positives but will take time to convert to improved margins. Tilray Brands Inc Q3 2026 Earnings Call Highlights
• Negative Sentiment: Analyst downgrade and tempered expectations — TD Cowen and other firms reduced targets/expectations, weighing on sentiment and amplifying the sell-off. TD Cowen Has Lowered Expectations for Tilray Brands
• Negative Sentiment: Mixed profitability and margin pressure — despite narrower losses, some outlets flagged a Q3 EPS miss or continued GAAP losses and a deeply negative net margin, keeping investor concerns about near-term profitability elevated. Tilray Reports Q3 Loss, Beats Revenue Estimates (Zacks)
• Negative Sentiment: Immediate market reaction was negative — several market pieces explain the sell-off (profitability skepticism, beverage margin concerns, and analyst actions) despite the revenue beat. Tilray Sinks 4%: 3 Reasons the Market Isn’t Impressed (Yahoo)

About Tilray Brands

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.